KR20180021697A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20180021697A
KR20180021697A KR1020177035629A KR20177035629A KR20180021697A KR 20180021697 A KR20180021697 A KR 20180021697A KR 1020177035629 A KR1020177035629 A KR 1020177035629A KR 20177035629 A KR20177035629 A KR 20177035629A KR 20180021697 A KR20180021697 A KR 20180021697A
Authority
KR
South Korea
Prior art keywords
cancer
nuc
treatment
leukemia
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177035629A
Other languages
English (en)
Korean (ko)
Inventor
휴 그리피스
크리스 매기건
크리스 페퍼
Original Assignee
뉴카나 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20180021697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴카나 피엘씨 filed Critical 뉴카나 피엘씨
Publication of KR20180021697A publication Critical patent/KR20180021697A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G01N33/57496—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020177035629A 2015-05-14 2015-05-14 암 치료 Ceased KR20180021697A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
KR20180021697A true KR20180021697A (ko) 2018-03-05

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035629A Ceased KR20180021697A (ko) 2015-05-14 2015-05-14 암 치료

Country Status (26)

Country Link
US (3) US20180289733A1 (cg-RX-API-DMAC7.html)
EP (2) EP3197456B2 (cg-RX-API-DMAC7.html)
JP (1) JP6761852B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180021697A (cg-RX-API-DMAC7.html)
CN (2) CN115837028A (cg-RX-API-DMAC7.html)
AU (2) AU2015394135B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017024461B1 (cg-RX-API-DMAC7.html)
CA (1) CA2985540C (cg-RX-API-DMAC7.html)
CY (1) CY1120516T1 (cg-RX-API-DMAC7.html)
DK (1) DK3197456T3 (cg-RX-API-DMAC7.html)
EA (1) EA201792509A1 (cg-RX-API-DMAC7.html)
ES (1) ES2668377T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180762T1 (cg-RX-API-DMAC7.html)
HU (1) HUE038541T2 (cg-RX-API-DMAC7.html)
IL (1) IL255591B (cg-RX-API-DMAC7.html)
LT (1) LT3197456T (cg-RX-API-DMAC7.html)
MX (2) MX390506B (cg-RX-API-DMAC7.html)
MY (1) MY192081A (cg-RX-API-DMAC7.html)
PH (1) PH12017502086B1 (cg-RX-API-DMAC7.html)
PL (1) PL3197456T3 (cg-RX-API-DMAC7.html)
PT (1) PT3197456T (cg-RX-API-DMAC7.html)
RS (1) RS57371B1 (cg-RX-API-DMAC7.html)
SI (1) SI3197456T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800303T1 (cg-RX-API-DMAC7.html)
TR (1) TR201806642T4 (cg-RX-API-DMAC7.html)
WO (1) WO2016181093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
LT3224268T (lt) 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
BR112018003594A2 (pt) 2015-09-25 2018-09-25 Hoffmann La Roche cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
RS62593B1 (sr) 2015-12-11 2021-12-31 NuCana plc Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
HUE050290T2 (hu) * 2015-12-23 2020-11-30 NuCana plc Kombinált terápia
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
CA3008769A1 (en) * 2015-12-23 2017-06-29 NuCana plc Combination therapy comprising nuc-1031 and cisplatin
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
EP3863674A2 (en) 2018-10-12 2021-08-18 The Regents of the University of Colorado, a body corporate Compositions and methods for reducing cancer stem cells
CN117462555B (zh) * 2021-01-31 2025-12-30 兰州大学 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS

Also Published As

Publication number Publication date
WO2016181093A1 (en) 2016-11-17
JP2018515618A (ja) 2018-06-14
AU2015394135B2 (en) 2021-09-16
EP3197456B1 (en) 2018-04-04
HUE038541T2 (hu) 2018-10-29
EP3415149A1 (en) 2018-12-19
BR112017024461B1 (pt) 2023-04-04
AU2015394135A1 (en) 2017-12-14
BR112017024461A2 (pt) 2018-07-24
DK3197456T3 (en) 2018-06-06
MY192081A (en) 2022-07-26
US20230226092A1 (en) 2023-07-20
PL3197456T3 (pl) 2018-09-28
US20210100825A1 (en) 2021-04-08
IL255591A (en) 2018-01-31
JP6761852B2 (ja) 2020-09-30
EP3197456B2 (en) 2023-10-11
SMT201800303T1 (it) 2018-07-17
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
EA201792509A1 (ru) 2018-05-31
US20180289733A1 (en) 2018-10-11
MX390506B (es) 2025-03-20
RS57371B1 (sr) 2018-08-31
CN115837028A (zh) 2023-03-24
PH12017502086B1 (en) 2022-12-09
TR201806642T4 (tr) 2018-06-21
MX2017014544A (es) 2018-09-26
PH12017502086A1 (en) 2018-04-30
SI3197456T1 (en) 2018-08-31
MX374946B (es) 2025-03-06
LT3197456T (lt) 2018-07-10
IL255591B (en) 2021-10-31
CA2985540C (en) 2021-08-24
CN107835687A (zh) 2018-03-23
EP3197456A1 (en) 2017-08-02
ES2668377T3 (es) 2018-05-17
MX2020009154A (es) 2022-03-08
HRP20180762T1 (hr) 2018-08-24
AU2021277614A1 (en) 2021-12-23
PT3197456T (pt) 2018-05-22

Similar Documents

Publication Publication Date Title
US20230226092A1 (en) Cancer treatments based on gemcitabine prodrugs
US20230218655A1 (en) Cancer treatments
JP2024527087A (ja) スピロノラクトン及びアシルフルベンの組み合わせによるがんの処置
JP6810763B2 (ja) がん治療
HK1261423A1 (en) Cancer treatments
HK1237283A1 (en) Cancer treatments
HK1237283B (en) Cancer treatments
EA040796B1 (ru) Лечение рака

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000